A5049089221- Head and Neck Cancer Studies
- Lung Cancer Research Studies
- Endometrial and Cervical Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Uterine Myomas and Treatments
- Liver Disease Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Hepatitis C virus research
- Neuroblastoma Research and Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
Institut Català d'Ornitologia
2023-2024
Institut Català d'Oncologia
2022-2024
Universitat de Barcelona
2024
Duran i Reynals Hospital
2024
Institut Català de Traumatologia i Medicina de l'Esport
2022
<h3>Introduction/Background</h3> In high-grade endometrial cancer (HGEC), the accuracy of tumor staging plays a pivotal role in determining therapeutic strategies and influencing patient prognoses. This study aimed to describe changes assess concordance International Federation Gynecology Obstetrics (FIGO-2009) before after surgery HGEC. <h3>Methodology</h3> A retrospective conducted at University Hospital Bellvitge (HUB), including 119 patients diagnosed with HGEC (grade-3 tumors), between...
<h3>Introduction/Background</h3> Lymphatic assessment in high-grade endometrial cancers (HGEC) has traditionally involved comprehensive lymph node dissection (LND). However, the use of sentinel (SLN) emerged as a potential alternative to this approach. We aim compared overall survival (OS), disease-free (DFS), positive rate (PLNR) and complications between both techniques. <h3>Methodology</h3> A retrospective study, including 70 patients diagnosed with HGEC ostensibly staged at I-II...
TPS6125 Background: The prognosis of locally-advanced head and neck squamous cell carcinoma (LA-HNSCC) remains poor, with a 60% 5-year overall survival (OS) rate despite curative-intent therapies. Treatment intensification strategies antiPD-(L)1 agents given concurrently to (chemo)radiotherapy (CRT) have failed improve survival. New radiosensitizing such as PARP inhibitors shown encouraging results in early studies, are special interest cisplatin-unfit patients (pts) (Moutafi et al. 2021)....
Objectives Anti-PD-(L)1 agents changed the landscape of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treatment. Previous studies showed improved response rates to salvage chemotherapy (SCT) after progression anti-PD-(L)1 agents. This study aims evaluate outcomes SCT identify predictors survival in patients with R/M HNSCC. Materials methods Retrospective cohort analysis 63 treated antiPD-(L1)-based therapy between January 2015 August 2022. The overall rate (ORR)...
Introduction The first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability not universal and elderly patients are underrepresented in clinical trials. There little evidence of efficacy tolerability under systemic treatment. aims this study were to characterize the profile treated with sorafenib, assess their survival safety order extrapolate eligibility Methods Retrospective multicentre HCC aged ≥75 years old sorafenib from...